Clinical course of bucillamine-induced nephropathy in patients with rheumatoid arthritis

Clinical and Experimental Nephrology

Volumn 7, Issue 4, 2003, Pages 275-278

  Obayashi, Mie ^a   Uzu, Takashi ^a   Harada, Tamaki ^a   Yamato, Masafumi ^a   Takahara, Ken ^a   Yamauchi, Atsushi ^a  

^a OSAKA ROSAI HOSPITAL   (Japan)

Author keywords

Bucillamine; Membranous nephropathy; Proteinuria; Rheumatoid arthritis

Indexed keywords

BUCILLAMINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DOSE RESPONSE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY FUNCTION; MALE; MEMBRANOUS GLOMERULONEPHRITIS; PROTEINURIA; RECURRENT DISEASE; RHEUMATOID ARTHRITIS;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CYSTEINE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PROTEINURIA;

EID: 0348049698     PISSN: 13421751     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10157-003-0252-0     Document Type: Article

References (17)

1. Boers M. Renal disorders in rheumatoid arthritis. Semin Arthritis Rheum 1990;20:57-68.
2. Nakano M, Ueno M, Nishi S, Shimada H, Hasegawa H, Watanabe T, et al. Analysis of renal pathology and drug history in 158 Japanese patients with rheumatoid arthritis. Clin Nephrol 1998;50:154-60.
3. Tubbs R, Valenzuela R, McCormack L, Pohl M. Gold nephropathy. N Engl J Med 1977;296:1413-4.
4. Hall C, Fothergill N, Blackwell M, Harrison P, MacKenzie J, MacIver A. The natural course of gold nephropathy: long term study of 21 patients. BMJ 1987;295:745-8.
5. Hall C, Jawad S, Harrison P, MacKenzie J, Bacon P, Klouda P, et al. Natural course of penicillamine nephropathy: a long term study of 33 patients. BMJ 1988;296:1083-6.
6. Howard-Lock H, Lock C, Mewa A, Kean W. D-penicillamine: chemistry and clinical use in rheumatic disease. Semin Arthritis Rheum 1986;15:251-81.
7. Ishikawa K, Sakaguchi M. SA 96 (N-(2-mercapto-2-methylpropanoyl)-L-cysteine) in rheumatoid arthritis. Scand J Rheumatol 1986;15:85-90.
8. Goto M, Sasano M, Nishioka K. Decrease in disease activity and concomitant increase in the percentage of peripheral blood suppressor T-cells in rheumatoid arthritis by a newly synthesized slow-acting anti-rheumatic drug (bucillamine). Int J Immunopharmacol 1989;11:327-31.
9. Yoshida A, Morozumi K, Suganuma T, Sugito K, Ikeda M, Oikawa T, et al. Clinicopathological findings of bucillamine-induced nephrotic syndrome in patients with rheumatoid arthritis. Am J Nephrol 1991;11:264-88.
10. Kawasaki Y, Suzuki J, Sike T, Isome M, Nozawa R, Suzuki S, et al. Bucillamine-induced nephropathy in a child with juvenile rheumatoid arthritis and Kartagener's syndrome. Pediatr Int 2000;42:316-8.
11. Nagahama K, Matsushita H, Hara M, Ubara Y, Hara S, Yamada A. Bucillamine induces membranous glomerulonephritis. Am J Kidney Dis 2002;39:706-12.
12. Arnett F, Edworthy S, Bloch D, McShane D, Fries J, Cooper N, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
13. Koseki Y, Terai C, Moriguchi M, Uesato M, Kamatani N. A prospective study of renal disease in patients with early rheumatoid arthritis. Ann Rheum Dis 2001;60:327-31.
14. Figueroa J, Waxman J. Membranous nephropathy in rheumatoid arthritis. South Med J 1982;75:480-2.
15. Amersi F, Nelson S, Shen X, Kato H, Melinek J, Kupiec-Weglinski J, et al. Bucillamine, a thiol antioxidant, prevents transplantation associated reperfusion injury. Proc Natl Acad Sci USA 2002;99:8915-20.
16. Horwitz L, Sherman N. Bucillamine prevents myocardial reperfusion injury. J Cardiovasc Pharmacol 2001;38:859-67.
17. Dodd MJ, Griffiths ID, Thompson M. Adverse reactions to D-penicillamine after gold toxicity. BMJ 1980;21:1498-9.